After seeing so many biotech share prices jump or plummet based on drug trials well before the drug is even approved, it is refreshing to discuss a company like Regeneron (Nasdaq: REGN ) . Regeneron's Eylea is experiencing incredible growth worldwide as a treatment for wet age-related macular degeneration, and the company is enjoying soaring profitability as a result. The stock is far from cheap, priced at 35 times forward earnings estimates, but Eylea has just gotten final approval from the European Commission for its macular degeneration indication in Europe, which means yet another market to add to the drug's dizzying growth story and more upward expansion from here.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
RSS Headlines
Fool UK
Comments from our Foolish Readers
Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the
Report this Comment icon found on every comment.
Report this Comment On November 28, 2012, at 11:40 PM, actionorprofits wrote:
Regeneron may trade higher but it's definitely losing momentum and struggling to hold its new highs.
There is also a story circulating about how a new drug will make Eylea and Lucentis both obsolete in less than 2 years.
Pretty scary stuff for Regeneron and ot looks like Regenero's loss will be another's gain . . . see why . . . http://bit.ly/QlwbY5
Add your comment.